Katyayani (Katya) Papatla, MD, MPH
she/her/hers
Assistant Professor of Obstetrics, Gynecology and Reproductive SciencesCards
About
Research
Publications
2025
A phase 2 trial of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability (NCT02899793): Updated survival and response analyses
Ettorre V, Bellone S, Greenman M, McNamara B, Palmieri L, Sethi N, Demirkiran C, Papatla K, Kailasam A, Siegel E, Ratner E, Santin A. A phase 2 trial of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability (NCT02899793): Updated survival and response analyses. Gynecologic Oncology 2025, 197: 110-115. PMID: 40334308, DOI: 10.1016/j.ygyno.2025.04.591.Peer-Reviewed Original ResearchProgression free survivalWhole-exome sequencingImmune checkpoint inhibitorsOverall survivalEndometrial cancerMicrosatellite instability-highCheckpoint inhibitorsFree survivalFollow-upResponse to immune checkpoint inhibitorsPatients treated with pembrolizumabProspective phase II studyExome sequencingResponse rateRecurrent platinum-resistantPhase II studyPhase 2 trialOverall survival dataEndometrial cancer patientsMLH-1MSI-H patientsFoundationOne platformImproved OSUpdate survivalPrognostic significancePreclinical Activity of Datopotamab Deruxtecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2, in Uterine Serous Carcinoma.
Greenman M, Demirkiran C, Bellone S, Hartwich T, McNamara B, Ettorre V, Santin N, Sethi N, Yang-Hartwich Y, Papatla K, Ratner E, Santin A. Preclinical Activity of Datopotamab Deruxtecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2, in Uterine Serous Carcinoma. Cancer Research Communications 2025, 5: 774-782. PMID: 40299780, PMCID: PMC12062949, DOI: 10.1158/2767-9764.crc-25-0057.Peer-Reviewed Original ResearchConceptsTrophoblast cell surface antigen 2Uterine serous carcinomaAntibody-dependent cell-mediated cytotoxicityAntibody-drug conjugatesCell-mediated cytotoxicitySerous carcinomaPreclinical activityCell linesTargets trophoblast cell-surface antigen-2Presence of peripheral blood lymphocytesTreatment of uterine serous carcinomaInduce antibody-dependent cell-mediated cytotoxicityPrimary USC cell linesRecurrent uterine serous carcinomaUSC xenograftsUterine serous carcinoma cell linesAntigen 2In vivoPrimary tumor cell linesTROP2 overexpressionBiomarker-targeted therapiesControl ADCChromium release assayHigher recurrence rateTumor growth suppression
2024
Mitigating disparity?: Treatment patterns, survival, and recurrence rates by race, ethnicity, and hospital site across a large urban health system
Papatla K, Orfanelli T, Stoffels G, Layne T, Baldwin E, Leibold A, Blank S, Cohen S. Mitigating disparity?: Treatment patterns, survival, and recurrence rates by race, ethnicity, and hospital site across a large urban health system. Gynecologic Oncology Reports 2024, 53: 101372. PMID: 38584803, PMCID: PMC10997945, DOI: 10.1016/j.gore.2024.101372.Peer-Reviewed Original Research
2023
O5 Does race impact surgical management of cervical cancer: An SGO clinical outcomes registry analysis
Flint M, Papatla K, Holtzman S, Blank S. O5 Does race impact surgical management of cervical cancer: An SGO clinical outcomes registry analysis. Gynecologic Oncology 2023, 173: s3-s4. DOI: 10.1016/j.ygyno.2023.05.022.Peer-Reviewed Original Research
2022
2022-RA-631-ESGO The impact of COVID 19 on cervical cancer screening and triage
Velasquez J, Papatla K, Kaplowitz E, Coughlin A, Zachem A, Goldberger C, Blank S. 2022-RA-631-ESGO The impact of COVID 19 on cervical cancer screening and triage. International Journal Of Gynecological Cancer 2022, 32: a374-a375. DOI: 10.1136/ijgc-2022-esgo.803.Peer-Reviewed Original ResearchDoes race impact uterine cancer surgical treatment: An SGO Clinical Outcomes Registry analysis (056)
Saleh M, Papatla K, Carr C, Layne T, Rocconi R, Timmins P, Lachance J, Straughn M, Dewdney S, Blank S. Does race impact uterine cancer surgical treatment: An SGO Clinical Outcomes Registry analysis (056). Gynecologic Oncology 2022, 166: s38. DOI: 10.1016/s0090-8258(22)01275-6.Peer-Reviewed Original Research
2021
COVID-19 and Gynecologic Oncology: What Have We Learned?
. COVID-19 and Gynecologic Oncology: What Have We Learned? Current Treatment Options In Oncology 2021, 22: 117. PMID: 34812973, PMCID: PMC8609172, DOI: 10.1007/s11864-021-00905-5.Peer-Reviewed Original Research
2020
Retrospective Implementation of Algorithm for Route of Hysterectomy in Resident Clinic May Increase Rates of Vaginal Hysterectomy
Papatla K, Aioub M, Gee T, Harmon K, Sanserino K. Retrospective Implementation of Algorithm for Route of Hysterectomy in Resident Clinic May Increase Rates of Vaginal Hysterectomy. Journal Of Minimally Invasive Gynecology 2020, 27: s80. DOI: 10.1016/j.jmig.2020.08.620.Peer-Reviewed Original ResearchQuality of Care and Communication With Limited English Proficiency (LEP) Obstetric Patients [37J]
Sanserino K, Papatla K, Aioub M, Gee T, Datwani H. Quality of Care and Communication With Limited English Proficiency (LEP) Obstetric Patients [37J]. Obstetrics And Gynecology 2020, 135: 112s-113s. DOI: 10.1097/01.aog.0000664384.21313.1a.Peer-Reviewed Original Research
2019
Second primary anal and oropharyngeal cancers in cervical cancer survivors
. Second primary anal and oropharyngeal cancers in cervical cancer survivors. American Journal Of Obstetrics And Gynecology 2019, 221: 478.e1-478.e6. PMID: 31128108, DOI: 10.1016/j.ajog.2019.05.025.Peer-Reviewed Original Research
Academic Achievements & Community Involvement
Clinical Care
Overview
Katyayani (Katya) Papatla, MD, MPH, is a gynecologic oncologist specializing in cancers of the female reproductive system, including ovarian, uterine, cervical, vulvar, and vaginal cancers.
Dr. Papatla is dedicated to supporting her patients and finds inspiration in their strength and resilience. "It is such a privilege to share this journey with my patients, and I am constantly inspired by their stories," she says.
She advises women to be vigilant about their health, encouraging annual gynecological visits and prompt attention to symptoms such as postmenopausal bleeding, persistent abdominal pain, or unexpected weight loss. "Don't be afraid to listen to your body and see your physician if something feels off,” she says.
Dr. Papatla received her medical degree and a master's in public health from the University of Miami Miller School of Medicine. She completed her residency at Temple University Hospital and a fellowship in gynecologic oncology at the Icahn School of Medicine at Mount Sinai. She is an assistant professor of obstetrics, gynecology and reproductive sciences at Yale School of Medicine.
Clinical Specialties
Gynecology; Minimally Invasive Gynecology
Fact Sheets
Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
Learn More on Yale MedicineUterine Sarcoma
Learn More on Yale MedicineUterine Cancer
Learn More on Yale Medicine
Yale Medicine News
News
News
- April 21, 2025
Yale Cancer Center Research Breakthroughs Unveiled at AACR Annual Meeting
- March 20, 2025
Smilow Cancer Hospital Gynecologic Oncology Expertise in Fairfield County
- November 07, 2024
Yale Ob/Gyn Faculty Present the Latest in Gynecologic Oncology at Memorial Conference
- September 27, 2024
Katyayani (Katya) Papatla, MD/MPH, in honor of Gynecologic Cancer Awareness Month
Get In Touch
Contacts
Appointment Number
Administrative Support
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.